Senti Bio Q3 net loss $14.9M; cash $39.4M; Celest partnership up to $156M

Senti Biosciences, Inc.

2023-Q3 EPS reported -$1.18 revenue$2,561,000

Net loss $14.9M ($0.34/share) includes non-recurring $21.7M gain and $25.7M impairment from GeneFab transaction.
Cash and short-term investments $39.4M; expects to fund operations into Q4 2024.
SENTI-202 IND on track for clearance Q4 2023; Phase 1 trial for AML expected to start early 2024.
Celest collaboration for SENTI-301A: up to $156M milestones plus tiered royalties; first patient H1 2024 in China.
GeneFab transaction: $37.8M total consideration; $18.9M at closing, $18.9M in installments 2024-2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Senti Biosciences, Inc. reported third quarter of 2023 results: net income 14.9, EPS 0.34.

Period: third quarter of 2023
Net income: 14.9
EPS: 0.34
Result: reported results

Exact text from the filing

Net loss was $14.9 million, or $0.34 per basic and diluted share, for the quarter ended September 30, 2023, which included a non-recurring $21.7 million gain from discontinued operations, as well as a non-recurring $25.7 million impairment for leasehold improvements, both related to the GeneFab transaction.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.